New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2012
06:14 EDTJNJ, BCS, DB, LYG, STD, JPM, DOW, AEG, RY, ING, RIMM, CS, UBS, BBVA, RBSOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Europe's program to defuse its financial crisis by injecting cash into the banking system is running out of energy as interest rates rise and some banks have little cash left, the Wall Street Journal reports...Dow Chemical (DOW) and other chemical companies see new opportunities in the enormous domestic deposits of gas, the Wall Street Journal reports...REUTERS: U.S. coal exports to China could more than double to over 12M tons in 2012 due to depressed freight rates and a decline in U.S. demand, says Xcoal Energy & Resources CEO Thrasher, Reuters reports...Johnson & Johnson (JNJ) received EU clearance to purchase Swiss medical device maker Synthes for about $21B, Reuters reports...BLOOMBERG: Research In Motion (RIMM) is close to deciding on a financial adviser, and JPMorgan Chase (JPM) is said to be the leading candidate to help the company weigh strategy options, Bloomberg reports.
News For STD;RBS;ING;LYG;BBVA;RY;DB;UBS;AEG;BCS;CS;DOW;JNJ;RIMM;JPM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 13, 2015
17:50 EDTJNJPharmacyclics to showcase new 'promising' Imbruvica data at ASCO
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.
08:27 EDTUBSDOJ may scrap non-prosecution agreement with UBS over rigging, FT says
UBS had agreed in 2012 to a non-prosecution agreement with the Department of Justice to resolve allegations it rigged the benchmark rate and that deal was recently extended for an additional year to the end of 2015, but the DOJ is threatening the NPA as it pursue a new investigation of foreign exchange manipulation, said Financial Times. Reference Link
07:21 EDTCSCredit Suisse to hold a conference
4th Annual Disruptive Technology Conference is being held in San Francisco on May 13-14 with webcasted company presentations to begin on May 13 at 10:35 am; not all company presentations may be webcasted. Webcast Link
May 12, 2015
19:52 EDTRBSNomura, RBS could pay $805M in mortgage ruling, Reuters says
Subscribe for More Information
18:18 EDTLYGU.K. cuts stake in Lloyds to sub-20%, BBC says
Subscribe for More Information
14:13 EDTRY, JPMBove says it may be time to buy bank stocks
Subscribe for More Information
07:48 EDTBCS, DBStandard & Poor's to hold a summit
Subscribe for More Information
May 11, 2015
17:58 EDTJNJJ&J's Janssen gets complete response letter regarding sNDA for Invega Sustenna
Subscribe for More Information
15:53 EDTRBSJudge says Nomura misled Freddie, Fannie, HousingWire says
Subscribe for More Information
09:59 EDTJPMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:58 EDTRBS, UBS, JPM, BCSBarclays expected to pay GBP2B to settle forex rigging charges, FT says
Subscribe for More Information
08:18 EDTJPMBanks executives seek to push back on 'false, damaging' statements, WSJ reports
Subscribe for More Information
07:46 EDTJPMJPMorgan price traget raised to $73 from $68 at BofA/Merrill
BofA/Merrill raised Buy rated JPMorgan's price target to $73 following a meeting with Chairman Jamie Dimon. The analyst believes earnings surprises are likely and the market is over-discounting the impact of regulation. BofA/Merrill expects JPMorgan to benefit from its multi-dimensional model, EPS sensitivity to rising interest rates, and a shift in Fed monetary policy which will drive bond market volatility.
07:28 EDTJPMJPMorgan downgraded to Neutral from Buy at MKM Partners
Subscribe for More Information
07:14 EDTDBDeutsche Bank's head of structured finance leaving bank, Bloomberg reports
Subscribe for More Information
May 10, 2015
20:03 EDTUBS, JPMCiti, JPMorgan, UBS consider exiting U.K., Financial Times says
Citi (C), JPMorgan (JPM), and UBS (UBS) are considering exiting their London operations due to the U.K.'s bank levy, reports the Financial Times, citing people familiar with the matter. There is particular focus among the banks to reduce repurchase agreements, said three senior industry figures. The Financial Times notes that the recent Conservative win could see political maneuvers to reduce or renegotiate the levy, potentially persuading the banks to stay. Reference Link
19:25 EDTJNJCourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
16:54 EDTUBSUBS expands U.S. investment banking operations, WSJ says
Subscribe for More Information
14:56 EDTRBSBritain to wind down RBS stake later this year, Reuters says
Subscribe for More Information
14:05 EDTJNJJohnson & Johnson shares may deliver double-digit returns, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use